Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone781-457-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$105.56 million
Profitability
Miscellaneous
Employees133
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable
Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions
What is Anika Therapeutics' stock symbol?
Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
How were Anika Therapeutics' earnings last quarter?
Anika Therapeutics Inc (NASDAQ:ANIK) posted its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.25. The biotechnology company earned $29.70 million during the quarter, compared to the consensus estimate of $27.01 million. Anika Therapeutics had a net margin of 27.60% and a return on equity of 11.59%. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.53 earnings per share. View Anika Therapeutics' Earnings History.
When is Anika Therapeutics' next earnings date?
What price target have analysts set for ANIK?
5 analysts have issued 12 month price targets for Anika Therapeutics' stock. Their forecasts range from $29.00 to $58.00. On average, they expect Anika Therapeutics' stock price to reach $47.75 in the next twelve months. This suggests that the stock has a possible downside of 13.6%. View Analyst Price Targets for Anika Therapeutics.
What is the consensus analysts' recommendation for Anika Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Anika Therapeutics.
What are Wall Street analysts saying about Anika Therapeutics stock?
Here are some recent quotes from research analysts about Anika Therapeutics stock:
- 1. According to Zacks Investment Research, "Anika Therapeutics, Inc. is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. Anika's orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. " (9/26/2019)
- 2. Barrington Research analysts commented, "We are maintaining our OUTPERFORM investment rating on ANIK shares and are increasing our price target to $49 (from $45 previously). We arrive at our price target by attaching a 15x multiple to our 2020 adjusted EBITDA estimate. We assume $140 million in net cash 12 months from now." (7/25/2019)
Has Anika Therapeutics been receiving favorable news coverage?
Media headlines about ANIK stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anika Therapeutics earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Anika Therapeutics.
Are investors shorting Anika Therapeutics?
Anika Therapeutics saw a drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,020,000 shares, a drop of 10.2% from the September 15th total of 2,250,000 shares. Based on an average trading volume of 205,100 shares, the days-to-cover ratio is currently 9.8 days. Approximately 15.1% of the company's shares are short sold. View Anika Therapeutics' Current Options Chain.
Who are some of Anika Therapeutics' key competitors?
Some companies that are related to Anika Therapeutics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Antares Pharma (ATRS), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).
What other stocks do shareholders of Anika Therapeutics own?
Who are Anika Therapeutics' key executives?
Anika Therapeutics' management team includes the folowing people:
- Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
- Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
- Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
- Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
- Mr. Alexei Goraltchouk, VP of Operations
Who are Anika Therapeutics' major shareholders?
Anika Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (5.26%), Boston Trust Walden Corp (2.70%), Millennium Management LLC (1.35%), Stifel Financial Corp (0.65%), Capital Management Corp VA (0.35%) and SG Americas Securities LLC (0.33%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Institutional Ownership Trends for Anika Therapeutics.
Which major investors are selling Anika Therapeutics stock?
ANIK stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Teton Advisors Inc., Capital Management Corp VA, Foundry Partners LLC, Systematic Financial Management LP, Creative Planning, Stifel Financial Corp and Eqis Capital Management Inc.. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, Jeffery S Thompson, Joseph L Bower, Raymond J Land and Sylvia Cheung. View Insider Buying and Selling for Anika Therapeutics.
Which major investors are buying Anika Therapeutics stock?
ANIK stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, SG Americas Securities LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC, Alberta Investment Management Corp, Public Employees Retirement System of Ohio, State of Alaska Department of Revenue and Dupont Capital Management Corp. View Insider Buying and Selling for Anika Therapeutics.
How do I buy shares of Anika Therapeutics?
Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Anika Therapeutics' stock price today?
One share of ANIK stock can currently be purchased for approximately $55.27.
How big of a company is Anika Therapeutics?
Anika Therapeutics has a market capitalization of $788.70 million and generates $105.56 million in revenue each year. The biotechnology company earns $18.72 million in net income (profit) each year or $1.84 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.View Additional Information About Anika Therapeutics.
What is Anika Therapeutics' official website?
How can I contact Anika Therapeutics?
Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]
MarketBeat Community Rating for Anika Therapeutics (NASDAQ ANIK)
MarketBeat's community ratings are surveys of what our community members think about Anika Therapeutics and other stocks. Vote "Outperform" if you believe ANIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIK will underperform the S&P 500 over the long term. You may vote once every thirty days.
